The Unmet Need in Chronic Lymphocytic Leukemia: Impact of Comorbidity Burden
on Treatment Patterns and Outcomes in Elderly Patients
1328
(Baltimore, MD), Information Management Services, Inc.
(Silver Spring, MD), and the Surveillance, Epidemiology,
and End Results (SEER) Program tumor registries in the
creation of the SEER-Medicare database. The interpreta-
tion and reporting of these data are the sole responsibility
of the authors.
REFERENCES
[1] G. M. Dores, W. F. Anderson, R. E. Curtis, et al., “Chro-
nic Lymphocytic Leukaemia and Small Lymphocytic
Lymphoma: Overview of the Descriptive Epidemiology,”
British Journal of Haematology, Vol. 139, No. 5, 2007,
pp. 809-819.
http://dx.doi.org/10.1111/j.1365-2141.2007.06856.x
[2] J. G. Gribben, “Chronic Lymphocytic Leukemia: Plan-
ning for an Aging Population,” Expert Review of Antican-
cer Therapy, Vol. 10, No. 9, 2010, pp. 1389-1394.
http://dx.doi.org/10.1586/era.10.127
[3] N. A. Howlader, M. Krapcho, et al., “SEER Cancer Sta-
tistics Review, 1975-2009 (Vintage 2009 Populations),”
National Cancer Institute, Bethesda, 2011.
[4] R. Siegel, C. DeSantis, K. Virgo, et al., “Cancer Treat-
ment and Survivorship Statistics, 2012,” CA: A Cancer
Journal for Clinicians, Vol. 62, No. 4, 2012, pp. 220-241.
http://dx.doi.org/10.3322/caac.21149
[5] C. Zent, “Chronic Lymphocytic Leukemia in the Elderly:
Who Should Be Treated?” 2010 Educational Book, 2010.
http://www.asco.org/ascov2/Education+&+Training/Educ
ational+Book?&vmview=edbk_detail_view&confID=74
&abstractID=60
[6] L. Smolej, “How I Treat Elderly or Comorbid Patients
with Chronic Lymphocytic Leukemia,” Acta Medica
(Hradec Kralove), Vol. 53, 2010, pp. 213-220.
[7] B. Eichhorst, V. Goede and M. Hallek, “Treatment of El-
derly Patients with Chronic Lymphocytic Leukemia,”
Leukemia & Lymphoma, Vol. 50, No. 2, 2009, pp. 171-
178. http://dx.doi.org/10.1080/10428190802688517
[8] J. C. Byrd, K. Rai, B. L. Peterson, et al., “Addition of
Rituximab to Fludarabine May Prolong Progression-Free
Survival and Overall Survival in Patients with Previously
Untreated Chronic Lymphocytic Leukemia: An Updated
Retrospective Comparative Analysis of CALGB 9712
and CALGB 9011,” Blood, Vol. 105, No. 1, 2005, pp 49-
53. http://dx.doi.org/10.1182/blood-2004-03-0796
[9] M. Hallek, K. Fischer, G. Fingerle-Rowson, et al., “Addi-
tion of Rituximab to Fludarabine and Cyclophosphamide
in Patients with Chronic Lymphocytic Leukaemia: A Ran-
domised, Open-Label, Phase 3 Trial,” Lancet, Vol. 376,
No. 9747, 2010, pp. 1164-1174.
http://dx.doi.org/10.1016/S0140-6736(10)61381-5
[10] P. Thurmes, T. Call, S. Slager, et al., “Comorbid Condi-
tions and Survival in Unselected, Newly Diagnosed Pa-
tients with Chronic Lymphocytic Leukemia,” Leukemia
& Lymphoma, Vol. 49, No. 1, 2008, pp. 49-56.
http://dx.doi.org/10.1080/10428190701724785
[11] L. Smolej, “Therapy of Elderly/Comorbid Patients with
Chronic Lymphocytic Leukemia,” Current Pharmaceuti-
cal Design, Vol. 18, No. 23, 2012, pp. 3399-3405.
http://dx.doi.org/10.2174/138161212801227096
[12] K. A. Foon, M. Boyiadzis, S. R. Land, et al., “Chemo-
immunotherapy with Low-Dose Fludarabine and Cyclo-
phosphamide and High Dose Rituximab in Previously Un-
treated Patients with Chronic Lymphocytic Leukemia,”
Journal of Clinical Oncology, Vol. 27, No. 4, 2009, pp.
498-503. http://dx.doi.org/10.1200/JCO.2008.17.2619
[13] F. Forconi, A. Fabbri, M. Lenoci, et al., “Low-Dose Oral
Fludarabine Plus Cyclophosphamide in Elderly Patients
with Untreated and Relapsed or Refractory Chronic Lym-
phocytic Leukaemia,” Hematological Oncology, Vol. 26,
No. 4, 2008, pp. 247-251.
http://dx.doi.org/10.1002/hon.868
[14] National Comprehensive Cancer Network, NCCN Clini-
cal Practice Guidelines in Oncology, Non-Hodgkin’s Lym-
phomas, Vol. 3, 2012.
[15] J. L. Warren, C. N. Klabunde, D. Schrag, et al., “Over-
view of the SEER-Medicare Data: Content, Research Ap-
plications, and Generalizability to the United States Eld-
erly Population,” Medical Care, Vol. 40, No. 8, 2002, pp.
IV-3-IV-18.
http://dx.doi.org/10.1097/00005650-200208001-00002
[16] A. L. Potosky, G. F. Riley, J. D. Lubitz, et al., “Potential
for Cancer Related Health Services Research Using a
Linked Medicare-Tumor Registry Database,” Medical
Care, Vol. 31, No. 8, 1993, pp. 732-748.
http://dx.doi.org/10.1097/00005650-199308000-00006
[17] N. C. Institute, “SEER-Medicare: How the SEER and
Medicare Data Are Linked,” 2007.
http://healthservices.cancer.gov/seermedicare/overview/li
nked.html
[18] J. L. Binet, A. Auquier, G. Dighiero, et al., “A New Prog-
nostic Classification of Chronic Lymphocytic Leukemia
Derived from a Multivariate Survival Analysis,” Cancer,
Vol. 48, No. 1, 1981, pp. 198-206.
http://dx.doi.org/10.1002/1097-0142(19810701)48:1<198
::AID-CNCR2820480131>3.0.CO;2-V
[19] K. R. Rai, A. Sawitsky, E. P. Cronkite, et al., “Clinical
Staging of Chronic Lymphocytic Leukemia,” Blood, Vol.
46, No. 2, 1975, pp. 219-234.
[20] M. D. Danese, R. I. Griffiths, M. Gleeson, et al., “An
Observational Study of Outcomes after Initial Infused
Therapy in Medicare Patients Diagnosed with Chronic
Lymphocytic Leukemia,” Blood, Vol. 117, No. 13, 2011,
pp. 3505-3513.
http://dx.doi.org/10.1182/blood-2010-08-301929
[21] J. L. Warren, L. C. Harlan, A. Fahey, et al., “Utility of the
SEER-Medicare Data to Identify Chemotherapy Use,”
Medical Care, Vol. 40, No. 8, 2002, pp. IV-55-IV-61.
http://dx.doi.org/10.1097/00005650-200208001-00008
[22] C. N. Klabunde, J. M. Legler, J. L. Warren, et al., “A Re-
fined Comorbidity Measurement Algorithm for Claims-
Based Studies of Breast, Prostate, Colorectal, and Lung
Cancer Patients,” Annals of Epidemiology, Vol. 17, No. 8,
2007, pp. 584-590.
http://dx.doi.org/10.1016/j.annepidem.2007.03.011
Copyright © 2013 SciRes. JCT